Incyclinide
Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions.[2][3] The drug lacks antibiotic properties but retains or enhances the inhibition of metalloproteinase.[4]
Clinical data | |
---|---|
Trade names | Metastat (proposed) |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H17NO7 |
Molar mass | 371.345 g·mol−1 |
3D model (JSmol) | |
| |
|
Mechanism of action
Like other tetracyclines, incyclinide inhibits matrix metalloproteinases.[4]
References
- Reuters: CollaGenex says incyclinide ineffective for rosacea
- H. Spreitzer (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
- ClinicalTrials.gov: Incyclinide
- Viera, MH, Perez, OA, Berman, B. "Incyclinide". Drugs of the Future. 32 (3): 209–214. doi:10.1358/dof.2007.032.03.1083308.CS1 maint: multiple names: authors list (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.